SPY299.08+3.64 1.23%
DIA250.25+5.37 2.19%
IXIC9,340.22+15.63 0.17%

Recap: Intersect ENT Q1 Earnings

Shares of Intersect ENT (NASDAQ:XENT) were unchanged at $13.49 after the company reported Q1 results. Quarterly Results Earnings per share decreased 54.29% year over year to ($0.54), which missed the estimate of ($0.44).

Benzinga · 05/11/2020 11:38

Shares of Intersect ENT (NASDAQ:XENT) were unchanged at $13.49 after the company reported Q1 results.

Quarterly Results

Earnings per share decreased 54.29% year over year to ($0.54), which missed the estimate of ($0.44).

Revenue of $19,826,000 lower by 25.67% year over year, which missed the estimate of $23,660,000.

Guidance

Earnings guidance hasn't been issued by the company for now.

Intersect ENT hasn't issued any revenue guidance for the time being.

Conference Call Details

Date: May 11, 2020

Time: 07:04 PM ET

Webcast URL: https://78449.choruscall.com/dataconf/productusers/xent/mediaframe/37432/indexr.html

Price Action

52-week high: $31.46

Company's 52-week low was at $5.97

Price action over last quarter: down 42.84%

Company Description

Intersect ENT Inc are a commercial drug delivery company committed to improving the quality of life for patients with ear, nose and throat conditions. It offer's PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis and PROPEL contour, a steroid-releasing implant to frontal and maxillary sinus ostia or openings of the dependent sinuses. The company generates revenues from the sale of our PROPEL family of products.